Considering A Xarelto Lawsuit? 12 Things You Need To Know

Xarelto has been linked to increasing the probability of significant uncontrollable bleeding events that result in hospitalization, serious injury and death. If you or a loved one took Xarelto and subsequently suffered one of the aforementioned outcomes, then you may be entitled to compensation from the manufacturers Johnson & Johnson and Bayer AG. As recently reported by BloodThinnerHelp.com, there are over 400 Xarelto lawsuits filed in the federal MDL. This number is expected to rise steadily in the coming months.

If you are considering filing a Xarelto lawsuit, the following 12 points are useful to know about the litigation:

• The FDA approved Xarelto (rivaroxaban) for several indications over the years. It was initially approved for preventing blood clots and DVT primarily in patients who underwent some hip or knee replacement surgeries. It was also approved to prevent blood clots in patients suffering from the prominent heart condition, atrial fibrillation. One of its more recent approvals was for the general reduction of incidents of blood clots in patients suffering from acute coronary syndrome.
• Xarelto (rivaroxaban) is manufactured by European drug conglomerate Bayer AG, who have US operations. Johnson & Johnson are also a key player in introducing Xarelto to the US by way of supporting the patent applications and FDA approval process through its research branch Janssen.
• In 2011, Xarelto (rivaroxaban) was approved for sale in the United States of America for the first time.
• To date, the manufacturers of the drug have not advised the medical community as to what medical intervention is needed to reverse the effects of Xarelto. With no known antidote, an internal or serious external bleed can cause death or serious injury. There have been reports that a startup company has found a reversal agent, however this has not yet been approved. Other blood thinners like Warfarin are reversed through taking Vitamin K, which assists with coagulation.
• During testing of Xarelto, a study revealed that more than 16,000 (73% of study subjects) reported an adverse side effect.
• The Food and Drug Administration has issued a warning that the premature discontinuance of Xarelto (Rivaroxaban) increases the risk of blood clots.
• Xarelto is considered to be a resounding success financially for its manufacturers. In 2013 they reported sales of $1.4 billion.
• In January 2014 – the first Xarelto lawsuit was filed alleging that the drug caused uncontrollable bleeding that lead to the death of the plaintiff’s husband.
• Since then hundreds of lawsuits have been filed. All have an unfortunate common theme: uncontrollable bleeding lead to a serious injury, hospitalization, or death.
• The most common injuries named in lawsuits are: pulmonary embolism, heart attack, stroke, brain hemorrhage, rectal bleeding, vaginal bleeding, epidural hematoma, and gastrointestinal bleeding.
• So many federal lawsuits have been filed that a mechanism known as a MDL has been formed to streamline the pretrial and discovery phases of the litigation. For federal cases, they will be transferred to federal court in Louisiana.
• In addition, many lawsuits were filed in Pennsylvania, and the court of common pleas have followed a similar strategy to process the discovery and pretrial motions via a consolidated mass tort group.

We hope the above gave you some background on the Xarelto litigation and where it stands as of today.

If you have any questions or comments, feel free to leave them below or you can reach me by using the contact information below:

Contact Information:

Name: Marc Goldich, Esq.

Phone: 866-425-8902